Alembic Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
APLLTD
Pharmaceuticals
Screen Alembic Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹823.70
▼
-2.00 (-0.24%)
Share Price BSE
₹822.80
▼
-2.35 (-0.28%)
Market Cap
₹16,190.90 Cr.
P/E Ratio (TTM)
25.67
P/B Ratio
3.05
EPS (TTM)
₹29.68
Dividend Yield
1.33%
Debt to Equity
0.18
52W High
₹1058.50
52W Low
₹743.65
Operating Margin
15.00%
Profit Margin
8.80%
Revenue (TTM)
₹1,784.00
EBITDA
₹286.00
Net Income
₹157.00
Total Assets
₹7,773.00
Total Equity
₹5,190.00
Alembic Pharmaceuticals Share Price History - Stock Screener Chart
Screen APLLTD historical share price movements with interactive charts. Analyze price trends and patterns.
Alembic Pharmaceuticals Company Profile - Fundamental Screener
Screen Alembic Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for APLLTD shares.
Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Chirayu R Amin
ISIN
INE901L01018
Alembic Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen APLLTD balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 7,773 | 6,446 | 6,183 | 7,122 | 6,709 | 5,989 | 4,778 | 3,941 | 2,689 | 2,429 |
| Current Assets | 4,088 | 3,079 | 2,910 | 2,861 | 2,652 | 2,463 | 1,958 | 1,825 | 1,373 | 1,511 |
| Fixed Assets | 2,524 | 2,547 | 2,398 | 1,798 | 1,788 | 1,552 | 1,159 | 993 | 799 | 708 |
| Liabilities | ||||||||||
| Total Liabilities | 7,773 | 6,446 | 6,183 | 7,122 | 6,709 | 5,989 | 4,778 | 3,941 | 2,689 | 2,429 |
| Current Liabilities | 171 | 172 | 175 | 168 | 361 | 1,047 | 570 | 576 | 94 | 84 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 5,190 | 4,818 | 4,371 | 5,238 | 5,067 | 3,190 | 2,718 | 2,220 | 1,902 | 1,597 |
| Share Capital | 39 | 39 | 39 | 39 | 39 | 38 | 38 | 38 | 38 | 38 |
| Reserves & Surplus | 5,152 | 4,779 | 4,331 | 5,198 | 5,028 | 3,182 | 2,681 | 2,182 | 1,865 | 1,560 |
Screen APLLTD income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,784 | 1,717 | 1,919 | 1,521 | 1,564 | 1,678 | 1,703 | 1,407 | 1,498 | 1,605 | 1,634 | 1,426 | 1,263 | 1,475 | 1,510 |
| Expenses | 1,498 | 1,430 | 1,595 | 1,257 | 1,325 | 1,409 | 1,433 | 1,203 | 1,288 | 1,387 | 1,364 | 1,268 | 1,255 | 1,244 | 1,274 |
| EBITDA | 286 | 287 | 324 | 263 | 239 | 270 | 270 | 205 | 210 | 218 | 269 | 158 | 9 | 231 | 236 |
| Operating Profit % | 15.00% | 16.00% | 17.00% | 17.00% | 15.00% | 15.00% | 15.00% | 14.00% | 13.00% | 13.00% | 16.00% | 10.00% | 1.00% | 16.00% | 16.00% |
| Depreciation | 69 | 74 | 76 | 70 | 69 | 71 | 70 | 74 | 66 | 68 | 69 | 123 | 67 | 68 | 67 |
| Interest | 25 | 24 | 24 | 11 | 13 | 19 | 22 | 14 | 14 | 16 | 15 | 7 | 9 | 12 | 15 |
| Profit Before Tax | 192 | 190 | 224 | 183 | 157 | 180 | 178 | 116 | 130 | 135 | 185 | 29 | -67 | 151 | 155 |
| Tax | 35 | 37 | 40 | 5 | 23 | 27 | 40 | -36 | 9 | -2 | 4 | 7 | -2 | 18 | 33 |
| Net Profit | 157 | 154 | 184 | 178 | 135 | 153 | 138 | 153 | 121 | 137 | 180 | 22 | -66 | 133 | 122 |
| EPS | 7.98 | 7.85 | 9.40 | 9.07 | 6.84 | 7.79 | 7.01 | 7.76 | 6.14 | 6.95 | 9.23 | 1.11 | -3.35 | 6.78 | 6.20 |
Alembic Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen APLLTD cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 88 | 803 | 724 | 552 | 1,463 | 449 | 812 | 312 | 329 | 948 |
| Investing Activities | -568 | -321 | -448 | -372 | -840 | -731 | -756 | -884 | -486 | -307 |
| Financing Activities | 444 | -438 | -262 | -217 | -597 | 155 | 59 | 503 | -129 | -224 |
| Net Cash Flow | -37 | 45 | 14 | -37 | 26 | -127 | 115 | -69 | -286 | 417 |
Screen APLLTD shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 69.67% | 69.67% | 69.74% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% |
| FII Holding | 3.94% | 3.96% | 4.05% | 4.46% | 4.32% | 3.94% | 4.17% | 0.00% |
| DII Holding | 16.43% | 16.46% | 16.30% | 15.38% | 15.47% | 16.05% | 16.06% | 13.31% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 7.07% | 7.01% | 6.93% | 7.41% | 7.48% | 7.36% | 7.26% | 9.08% |
| Other Holding | 2.88% | 2.89% | 2.99% | 3.14% | 3.13% | 3.04% | 2.90% | 8.00% |
| Shareholder Count | 91,336 | 89,013 | 89,969 | 76,567 | 74,829 | 91,429 | 93,944 | 103,811 |
Alembic Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen APLLTD dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹11.00 | 1.33% |
| 2024-March | ₹11.00 | 1.18% |
| 2023-March | ₹8.00 | 0.81% |
| 2022-March | ₹10.00 | 2.13% |
| 2021-March | ₹14.00 | 1.89% |
| 2020-March | ₹10.00 | 1.04% |
| 2019-March | ₹5.50 | 1.03% |
| 2018-March | ₹4.00 | 0.74% |
| 2017-March | ₹4.00 | 0.73% |
Alembic Pharmaceuticals Index Membership - Market Screener Classification
Screen APLLTD by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Alembic Pharmaceuticals Market Events Screener - Corporate Actions
Screen APLLTD market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-04 | 2025-11-04 | Quarterly Result Announcement | NA | -0.92% |
| 2025-08-05 | 2025-08-05 | Annual General Meeting | NA | -1.57% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -6.22% |
| 2025-07-29 | 2025-07-29 | Dividend | ₹ 11.00 /share | 10.49% |
| 2025-05-06 | 2025-05-06 | Quarterly Result Announcement | NA | 6.54% |
| 2025-02-03 | 2025-02-03 | Quarterly Result Announcement | NA | -9.02% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | -3.68% |
| 2024-07-22 | 2024-07-22 | Annual General Meeting | NA | 27.73% |
| 2024-07-15 | 2024-07-15 | Dividend | ₹ 11.00 /share | -1.72% |
| 2023-07-28 | 2023-07-28 | Dividend | ₹ 8.00 /share | 30.61% |
| 2022-08-17 | 2022-08-18 | Dividend | ₹ 10.00 /share | -16.05% |
| 2021-07-19 | 2021-07-21 | Dividend | ₹ 14.00 /share | -4.47% |
Alembic Pharmaceuticals Competitors Screener - Peer Comparison
Screen APLLTD competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,705 | 40.28 | 54,729 | 9.71% | 10,980 | 58.99 |
| Divis Laboratories | 176,338 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 138,499 | 62.26 | 11,539 | 6.99% | 1,911 | 80.95 |
| Cipla | 118,573 | 22.75 | 28,410 | 7.12% | 5,291 | 38.52 |
| Dr Reddys Laboratories | 103,728 | 18.27 | 33,741 | 16.73% | 5,725 | 40.17 |
| Lupin | 101,149 | 22.61 | 22,910 | 13.74% | 3,306 | 71.67 |
| Mankind Pharma | 95,432 | 52.17 | 12,744 | 20.90% | 2,007 | 64.16 |
| Zydus Life Science | 93,333 | 18.63 | 23,511 | 18.55% | 4,615 | 52.14 |
| Aurobindo Pharma | 71,752 | 20.91 | 32,346 | 9.43% | 3,484 | 61.25 |
| Alkem Laboratories | 69,425 | 28.04 | 13,458 | 3.70% | 2,216 | 63.97 |
Alembic Pharmaceuticals Company Announcements - News Screener
Screen APLLTD latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-12-26 | Closure of Trading Window | View |
| 2025-12-18 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-16 | Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-01 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-10 | Newspaper Publication | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-06 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |